US4172117A
(en)
*
|
1974-05-20 |
1979-10-23 |
Biotest-Serum-Institut Gmbh |
Method for the simultaneous measurement of antigens and their antibodies by solid-phase radioimmunoassay
|
US4225784A
(en)
*
|
1976-06-17 |
1980-09-30 |
Smith Kline Instruments, Inc. |
Covalently bound biological substances to plastic materials and use in radioassay
|
AT343822B
(de)
*
|
1976-08-20 |
1978-06-26 |
Immuno Ag |
Radioimmunologisches verfahren und einrichtung zur bestimmung von antigenen
|
JPS604422B2
(ja)
*
|
1976-10-07 |
1985-02-04 |
持田製薬株式会社 |
抗原の定量方法
|
USRE34394E
(en)
*
|
1978-01-23 |
1993-09-28 |
Baxter Diagnostics Inc. |
Method and composition for double receptor, specific binding assays
|
JPS608745B2
(ja)
*
|
1978-02-14 |
1985-03-05 |
三洋化成工業株式会社 |
免疫活性物質−つや消しガラス複合体,その製造法及び該複合体を含有してなる測定試薬
|
US4242322A
(en)
*
|
1978-06-07 |
1980-12-30 |
Electro-Nucleonics Laboratories, Inc. |
Methods and materials for detecting antigens and antibodies
|
US4393040A
(en)
*
|
1981-03-24 |
1983-07-12 |
Lopapa Institute, Inc. |
In-vitro diagnostic method for detection of acetylsalicylic acid ingestion
|
US4994373A
(en)
|
1983-01-27 |
1991-02-19 |
Enzo Biochem, Inc. |
Method and structures employing chemically-labelled polynucleotide probes
|
US5242798A
(en)
*
|
1983-07-21 |
1993-09-07 |
Scripps Clinic And Research Foundation |
Synthetic polypeptides corresponding to portions of proteinoids translated from brain-specific mRNAs, receptors, methods and diagnostics using the same
|
ATE23169T1
(de)
*
|
1983-07-21 |
1986-11-15 |
Scripps Clinic Res |
Synthetische polypeptide, die gehirnspezifischen mrnas translatierten proteinoidabschnitten entsprechen, sowie ihre anwendung fuer rezeptoren, methoden und diagnostik.
|
US5182082A
(en)
*
|
1991-01-23 |
1993-01-26 |
Becton, Dickinson And Company |
Multiple aliquot device for distributing a liquid solution into a well
|
US6168956B1
(en)
|
1991-05-29 |
2001-01-02 |
Beckman Coulter, Inc. |
Multiple component chromatographic assay device
|
US5998220A
(en)
*
|
1991-05-29 |
1999-12-07 |
Beckman Coulter, Inc. |
Opposable-element assay devices, kits, and methods employing them
|
US5877028A
(en)
*
|
1991-05-29 |
1999-03-02 |
Smithkline Diagnostics, Inc. |
Immunochromatographic assay device
|
US5348867A
(en)
*
|
1991-11-15 |
1994-09-20 |
George Georgiou |
Expression of proteins on bacterial surface
|
US5698686A
(en)
|
1994-10-20 |
1997-12-16 |
Arch Development Corporation |
Yeast telomerase compositions
|
US5807552A
(en)
*
|
1995-08-04 |
1998-09-15 |
Board Of Regents, The University Of Texas System |
Compositions for conferring immunogenicity to a substance and uses thereof
|
AU727445B2
(en)
*
|
1995-08-18 |
2000-12-14 |
Donald W Landry |
Detection of organic compounds through regulation of antibody-catalyzed reactions
|
US6689757B1
(en)
|
1996-02-12 |
2004-02-10 |
M.L. Laboratories Plc |
Methods for vaccination and vaccines therefor
|
US20020034732A1
(en)
*
|
1997-07-30 |
2002-03-21 |
Daniel J. Capon |
Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
|
US6610838B1
(en)
|
1997-09-10 |
2003-08-26 |
Symbicom Aktiebolag |
P13 antigens from Borrelia
|
AU2150900A
(en)
*
|
1998-11-16 |
2000-06-05 |
Board Of Regents, The University Of Texas System |
Hiv-specific t-cell induction
|
EP1343894A4
(en)
*
|
2000-11-02 |
2005-05-04 |
Univ Singapore |
AOPB GENE, PROTEIN, HOMOLOGISTS, FRAGMENTS AND VARIANTS THEREOF, AND THE USE THEREOF FOR PRESENTATION ON THE CELL SURFACE
|
US7847084B2
(en)
|
2002-12-20 |
2010-12-07 |
Board Of Regents, The University Of Texas System |
VMP-like sequences of pathogenic Borrelia species and strains
|
US20050002953A1
(en)
*
|
2003-05-06 |
2005-01-06 |
Jens Herold |
SARS-coronavirus virus-like particles and methods of use
|
US7910523B2
(en)
|
2003-05-23 |
2011-03-22 |
Board Of Regents, The University Of Texas System |
Structure based and combinatorially selected oligonucleoside phosphorothioate and phosphorodithioate aptamer targeting AP-1 transcription factors
|
EP1998800A2
(en)
|
2006-01-18 |
2008-12-10 |
University Of Chicago |
Compositions and methods related to staphylococcal bacterium proteins
|
CA2715042C
(en)
|
2007-02-02 |
2021-02-02 |
Baylor Research Institute |
Multivariable antigens complexed with targeting humanized monoclonal antibody
|
TWI422594B
(zh)
|
2007-02-02 |
2014-01-11 |
Baylor Res Inst |
經由樹狀細胞去唾液酸糖蛋白受體(dc-asgpr)接合抗原呈現細胞之藥劑
|
NZ593450A
(en)
|
2007-02-02 |
2012-08-31 |
Baylor Res Inst |
Vaccines based on targeting antigen to dcir expressed on antigen-presenting cells
|
MX2009008918A
(es)
*
|
2007-02-23 |
2009-09-14 |
Baylor Res Inst |
Activacion de celulas que presentan antigeno humano a traves de clec-6.
|
NZ594892A
(en)
*
|
2007-02-23 |
2012-12-21 |
Baylor Res Inst |
Therapeutic applications of activation of human antigen-presenting cells through dectin-1
|
CN101668772A
(zh)
|
2007-02-23 |
2010-03-10 |
贝勒研究院 |
通过树突细胞凝集素样氧化型ldl受体-1(lox-1)激活人抗原呈递细胞
|
WO2009059328A2
(en)
*
|
2007-11-02 |
2009-05-07 |
The Johns Hopkins University |
Multi- component l2 vaccine for prevention of human papillomavirus infection
|
EP2307048A4
(en)
*
|
2008-07-16 |
2012-02-29 |
Baylor Res Inst |
HIV VACCINE BASED ON TARGETING OF MAXIMIZED GAG AND NEF ON DENDRITIC CELLS
|
CN102333540B
(zh)
|
2008-10-06 |
2015-04-22 |
芝加哥大学 |
与细菌eap、emp和/或adsa蛋白相关的组合物和方法
|
EP2414387B1
(en)
|
2009-04-03 |
2015-12-16 |
University Of Chicago |
Compositions and methods related to protein a (spa) variants
|
US10080799B2
(en)
|
2010-02-12 |
2018-09-25 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Methods and compositions related to glycoprotein-immunoglobulin fusions
|
JP2013523818A
(ja)
|
2010-04-05 |
2013-06-17 |
ザ・ユニバーシティー・オブ・シカゴ |
免疫反応のエンハンサーとしてのプロテインA(SpA)抗体に関連する組成物および方法
|
EP2588120B1
(en)
|
2010-07-02 |
2017-11-15 |
The University of Chicago |
Compositions and methods related to protein a (spa) variants
|
EP2614074A1
(en)
|
2010-09-09 |
2013-07-17 |
The University of Chicago |
Methods and compositions involving protective staphylococcal antigens
|
US9567346B2
(en)
|
2010-10-29 |
2017-02-14 |
Life Technologies Corporation |
Biotin derivatives
|
US8945588B2
(en)
|
2011-05-06 |
2015-02-03 |
The University Of Chicago |
Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
|
US9968668B2
(en)
|
2012-04-26 |
2018-05-15 |
The University Of Chicago |
Staphylococcal coagulase antigens and methods of their use
|
WO2014052588A1
(en)
|
2012-09-27 |
2014-04-03 |
Research Development Foundation |
Attenuated chikungunya virus
|
US10358667B2
(en)
|
2013-03-07 |
2019-07-23 |
University Of Maryland, Baltimore |
Immunotherapeutic potential of modified lipooligosaccharides/lipid A
|
IL300029A
(en)
|
2014-05-16 |
2023-03-01 |
Baylor Res Institute |
Methods and preparations for the treatment of autoimmune and inflammatory conditions
|
US10662226B2
(en)
|
2016-10-28 |
2020-05-26 |
The Regents of the University of Caiifomia |
Synthetic beta-amyloid peptides capable of forming stable antigenic oligomers
|
WO2019183500A1
(en)
|
2018-03-23 |
2019-09-26 |
Hung Chiung Yu |
Coccidioides antigens and methods of their use
|
US11548938B2
(en)
|
2018-08-21 |
2023-01-10 |
Quidel Corporation |
DbpA antibodies and uses thereof
|
CN113811547B
(zh)
|
2019-03-27 |
2024-06-25 |
国家医疗保健研究所 |
具有cd40激活特性的重组蛋白
|
JP2023502712A
(ja)
|
2019-11-21 |
2023-01-25 |
インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) |
抗pd-1/il-15免疫サイトカインによる新しいpd-1標的免疫療法
|
US11376320B2
(en)
|
2020-03-05 |
2022-07-05 |
Iowa State University Research Foundation, Inc. |
Immunogenic and vaccine compositions against SARS-CoV-2
|
EP4149974A1
(en)
|
2020-05-13 |
2023-03-22 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Recombinant proteins with ox40 activating properties
|
JP2025504887A
(ja)
|
2022-01-28 |
2025-02-19 |
ファイザー・インク |
コロナウイルス抗原バリアント
|
WO2025017036A1
(en)
|
2023-07-17 |
2025-01-23 |
Institut National de la Santé et de la Recherche Médicale |
Alphavirus nsp3 helical tubular scaffolds
|
WO2025027492A1
(en)
|
2023-07-31 |
2025-02-06 |
Pfizer Inc. |
Coronavirus antigen variants
|